Cargando…

Budget Impact Analysis Of Subcutaneous Belimumab In Patients With Systemic Lupus Erythematosus In Spain

OBJECTIVE: To evaluate the budget impact and the direct costs of the introduction of subcutaneous belimumab (SC) into the Spanish National Health Service (NHS) for patients with systemic lupus erythematosus (SLE) in Spain. METHODS: This study was conducted from the Spanish NHS perspective with a tim...

Descripción completa

Detalles Bibliográficos
Autores principales:	Cevey, Maria, Calvo-Alén, Jaime, Crespo, Carlos, Robles-Marhuenda, Angel, Smolen, Lee, Cortés-Hernández, Josefina
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove 2019
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6901000/ https://www.ncbi.nlm.nih.gov/pubmed/31824182 http://dx.doi.org/10.2147/CEOR.S218464

Ejemplares similares

Belimumab in systemic lupus erythematosus
por: Vilas-Boas, Andreia, et al.
Publicado: (2015)

Belimumab in Systemic Lupus Erythematosus
por: Srivastava, Ankita
Publicado: (2016)

Evaluation of a novel autoinjector for subcutaneous self-administration of belimumab in systemic lupus erythematosus
por: Sheikh, Saira Z., et al.
Publicado: (2016)

Belimumab for systemic lupus erythematosus – Focus on lupus nephritis
por: Plüß, Marlene, et al.
Publicado: (2022)

Pharmacokinetics of Belimumab in Children With Systemic Lupus Erythematosus
por: Dimelow, Richard, et al.
Publicado: (2020)

Comparison of intravenous and subcutaneous exposure supporting dose selection of subcutaneous belimumab systemic lupus erythematosus Phase 3 program
por: Yapa, S Wickramaratne Senarath, et al.
Publicado: (2016)

Patient Evaluation of Satisfaction and Outcomes with an Autoinjector for Self-Administration of Subcutaneous Belimumab in Patients with Systemic Lupus Erythematosus
por: Dashiell-Aje, Ebony, et al.
Publicado: (2017)

Population Pharmacokinetic and Pharmacodynamic Analysis of Belimumab Administered Subcutaneously in Healthy Volunteers and Patients with Systemic Lupus Erythematosus
por: Struemper, Herbert, et al.
Publicado: (2017)

Subcutaneous formulation of belimumab in treatment of systemic lupus erythematosus: a critical review with focus on safety and satisfaction
por: Ahmed, Hamdy MA, et al.
Publicado: (2018)

Management of Pediatric Systemic Lupus Erythematosus: Focus on Belimumab
por: Guzman, Marla, et al.
Publicado: (2020)

Impact of Belimumab on Organ Damage in Systemic Lupus Erythematosus
por: Urowitz, Murray B., et al.
Publicado: (2022)

Efficacy and Safety of Subcutaneous Belimumab in Anti–Double‐Stranded DNA–Positive, Hypocomplementemic Patients With Systemic Lupus Erythematosus
por: Doria, A., et al.
Publicado: (2018)

Belimumab: First targeted biological treatment for systemic lupus erythematosus
por: Dubey, Ashok K., et al.
Publicado: (2011)

Real-World Effectiveness of Belimumab in the Treatment of Systemic Lupus Erythematosus: Pooled Analysis of Multi-Country Data from the OBSErve Studies
por: Collins, Christopher E., et al.
Publicado: (2020)

A 6-month open-label extension study of the safety and efficacy of subcutaneous belimumab in patients with systemic lupus erythematosus
por: Doria, A, et al.
Publicado: (2018)

Patient Satisfaction And Disease Control In Patients With Systemic Lupus Erythematosus Is Not Affected By Switching From Intravenous Belimumab To Subcutaneous Injections
por: Mucke, Johanna, et al.
Publicado: (2019)

Within-trial economic analysis of flare data from the BLISS-SC trial of subcutaneous belimumab in systemic lupus erythematosus
por: Lokhandwala, Tasneem, et al.
Publicado: (2021)

Prediction of Belimumab Pharmacokinetics in Chinese Pediatric Patients with Systemic Lupus Erythematosus
por: Zhou, Xuan, et al.
Publicado: (2021)

Belimumab in childhood systemic lupus erythematosus: A review of available data
por: Chen, Feng, et al.
Publicado: (2022)

Belimumab or anifrolumab for systemic lupus erythematosus? A risk-benefit assessment
por: Kirou, Kyriakos A., et al.
Publicado: (2022)

Belimumab in the treatment of systemic lupus erythematosus: high disease activity predictors of response
por: van Vollenhoven, Ronald F, et al.
Publicado: (2012)

Autoantibody and Cytokine Profiles during Treatment with Belimumab in Patients with Systemic Lupus Erythematosus
por: Parodis, Ioannis, et al.
Publicado: (2020)

Efficacy and safety of belimumab during maintenance therapy in patients with systemic lupus erythematosus
por: Miyazaki, Yusuke, et al.
Publicado: (2021)

The Safety and Efficacy of Rituximab and Belimumab in Systemic Lupus Erythematosus: A Systematic Review
por: Abid, Naushad, et al.
Publicado: (2023)

Efficacy and Safety of Subcutaneous Belimumab in Systemic Lupus Erythematosus: A Fifty‐Two–Week Randomized, Double‐Blind, Placebo‐Controlled Study
por: Stohl, William, et al.
Publicado: (2017)

An update on belimumab for the treatment of lupus
por: Thanou-Stavraki, Aikaterini, et al.
Publicado: (2011)

Elevated BLyS levels in patients with systemic lupus erythematosus: Associated factors and responses to belimumab
por: Roth, D A, et al.
Publicado: (2015)

Impact of concomitant medication use on belimumab efficacy and safety in patients with systemic lupus erythematosus
por: Schwarting, A, et al.
Publicado: (2016)

Impact of belimumab on patient-reported outcomes in systemic lupus erythematosus: review of clinical studies
por: Bangert, Elvira, et al.
Publicado: (2019)

Systemic Lupus Erythematosus-Associated Serositis Managed With Intravenous Belimumab: A Case Report
por: Mukkera, Srikanth, et al.
Publicado: (2022)

Short‐term clinical observations of belimumab in the treatment of recently diagnosed systemic lupus erythematosus
por: Wu, Chunye, et al.
Publicado: (2022)

Real-World Effectiveness of Belimumab in Systemic Lupus Erythematosus: A Systematic Literature Review
por: Huang, Shirley P., et al.
Publicado: (2022)

Efficacy and safety of belimumab in paediatric and adult patients with systemic lupus erythematosus: an across-study comparison
por: Brunner, Hermine I, et al.
Publicado: (2021)

Autoimmune Lupus Enteritis with Pan Gastrointestinal Involvement in an Adult Patient with Systemic Lupus Erythematosus: Complete Response to Belimumab
por: Shaik, Mohammed R., et al.
Publicado: (2023)

A Rare Case of Prototheca Algaemia in a Patient with Systemic Lupus Erythematosus and Recent Belimumab Infusion
por: Mejia-Otero, Carolina, et al.
Publicado: (2012)

Health Technology Assessment of Belimumab: A New Monoclonal Antibody for the Treatment of Systemic Lupus Erythematosus
por: Specchia, Maria Lucia, et al.
Publicado: (2014)

Safety, tolerability, pharmacokinetics and pharmacodynamics of belimumab in Japanese patients with mild-to-moderate systemic lupus erythematosus
por: Yamada, Masanori, et al.
Publicado: (2013)

BAFF-neutralizing interaction of belimumab related to its therapeutic efficacy for treating systemic lupus erythematosus
por: Shin, Woori, et al.
Publicado: (2018)

Belimumab and Rituximab in Systemic Lupus Erythematosus: A Tale of Two B Cell-Targeting Agents
por: Wise, Leanna M., et al.
Publicado: (2020)

Predictors of low disease activity and clinical remission following belimumab treatment in systemic lupus erythematosus
por: Parodis, Ioannis, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_40f7schfaegldf5rsbn4r77l9r